This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mitrunen, K. Articles by Hirvonen, A. Search for Related Content PubMed PubMed Citation Articles by Mitrunen, K. Articles by Hirvonen, A.

Steroid Metabolism Gene CYP17 Polymorphism and the Development of Breast Cancer¹

Department of Industrial Hygiene and Toxicology, Finnish Institute of Occupational Health, 00250 Helsinki, Finland [K. M., A. H.]; Unit of Cancer Epidemiology (INSERM U521), Gustave-Roussy Institute, 94805 Villejuif, France [N. J., S. B.]; Departments of Oncology [V. K.] and Surgery [M. E.], Kuopio University Hospital, 70211 Kuopio, Finland; Departments of Clinical Pathology and Forensic Medicine [V-M. K.] and Clinical Nutrition [M. U.], University of Kuopio, 70211 Kuopio, Finland; and International Agency for Research on Cancer, 69372 Lyon, France [H. V.]

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
The potential role of the polymorphism in the CYP17 gene was evaluated in a case-control study with 483 incident breast cancer patients and 482 population controls, all of homogenous Finnish origin. Our data disagree with the earlier suggestions that the minor A2 variant of CYP17 would pose an increased risk for developing advanced breast cancer. In contrast, a tendency of inverse association was found for premenopausal women carrying the A2 allele containing genotypes with a multivariate adjusted odds ratio of 0.58 approaching statistical significance (95% CI, 0.31–1.07). Agreeing with previous observations, the protective effect of later age at menarche (13 years) was mainly limited to women with A1/A1 genotype, although this could only be seen in premenopausal women (odds ratio, 0.34; 95% CI, 0.15–0.76). Similarly, we found a remarkably lower risk for premenopausal women with at least one child (odds ratio, 0.22; 95% CI, 0.07–0.62) to be mainly attributable to the A1/A1 genotype. CYP17 genotypes may thus modify individual breast cancer proneness in certain subpopulations, although they appear not to have any major modifying role in the risk of this malignancy overall. Because these findings are based on relatively small numbers in stratified analysis, they should, however, be interpreted with caution before being confirmed in future studies.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Endogenous exposure to circulating steroid hormones appears to be closely related to the development and progression of breast cancer (1) . Several factors affecting exposure to endogenous and exogenous sex hormones may modify individual susceptibility to this neoplasm. In agreement with this, early menarche, late menopause, postmenopausal obesity, alcohol consumption, and the use of estrogen replacement therapy have been shown to increase the risk of developing breast cancer, whereas early FFTP,³ lactation, and physical activity seem to protect from it (1) . Recent interest has been focused on polymorphisms in genes that control the metabolism or intracellular transport of sex hormones (2) .

The CYP17 gene codes for the cytochrome P450c17 enzyme, which mediates both steroid 17a-hydroxylase and 17,20-lyase activities and functions at key branch points in human steroidogenesis (3 , 4) . The 5' untranslated region of CYP17 contains a single T (in the A1 allele) to C (in the A2 allele) base substitution at position 1931 that creates an additional Sp-1-type (CCACC box) promoter motif between the initiation of translation and transcription start sites (5) . It has led to the reasoning that the A2 allele is associated with enhanced transcriptional activity. Because CYP17 has a fundamental role in steroid metabolism, it has been further reasoned that this allele may be associated with increased susceptibility to breast cancer.

Recently Feigelson et al. (6) found the A2 allele to be associated with higher serum estrogen and progesterone levels compared with the A1 allele. Subsequently, they found A2/A2 carriers to be half as likely current users of hormone replacement therapy compared with women with the A1/A1 genotype (OR, 0.52; 95% CI, 0.31–0.86; Ref. 7 ). In another study, women with the A2/A2 genotype had elevated levels of estrone and dehydroepiandrosterone (8) . On the basis of the above studies, the CYP17 polymorphism could indeed be an important modifier of the corresponding enzyme activity.

As for the potential role of CYP17 polymorphism in breast cancer risk, the studies completed thus far have given controversial results. In the first study by Feigelson et al. (9) , the women with A2 allele-containing genotypes were at 2.5-fold (95% CI, 1.07–5.94) risk for advanced breast cancer compared with the women without the allele. The reduced risk of breast cancer usually associated with a later age at menarche was also observed but was limited to women with the A1/A1 genotype (OR, 0.47; 95% CI, 0.22–0.98). This observation was recently supported in another study where the respective OR was 0.57 (95% CI, 0.36–0.90; Ref. 8 ). Recently Bergman-Jungestrom et al. (10) reported a significantly increased risk (OR, 2.0; 95% CI, 1.1–3.5) for young women (<37 years) carrying at least one A2 allele. In another study this allele was associated with a significantly increased risk (OR, 2.10; 95% CI, 1.04–4.27) for male, but not for female, breast cancer (11) . The other studies did not show any significant association between CYP17 genotypes and breast cancer risk (12, 13, 14, 15, 16) .

Most of the earlier studies have suffered from a small study size, racially diverse study populations, or deficiency of study design in terms of not selecting controls to match the cases by age and menopausal status. This has raised a need for large studies on the potential role of genes encoding for estrogen metabolism and transport enzymes in individual breast cancer proneness, recently emphasized by Coughlin and Piper (17) . We further investigated the potential role of CYP17 polymorphism in breast cancer proneness in a large study population consisting of 483 incident breast cancer patients and 482 healthy population controls, all of homogenous Finnish origin.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Study Population.
This case-control study is an extension of Kuopio Breast Cancer Study that follows the protocol of the International Collaborative Study of Breast and Colorectal Cancer coordinated by the European Institute of Oncology in Milan. All women with a suspicious breast lump or breast symptoms and living in the study area were invited to Kuopio University Hospital from 1990 to 1995. They were asked to participate in the study at the first hospital examination before either the patient or the interviewer knew the diagnosis. Body-size indicators (height, weight, waist and hip circumference) were recorded at the time of the interview (18) . Of the women who agreed to participate in the study, 516 were finally diagnosed with breast cancer, as were 12 of the women who had refused to participate. The participation rate of the cases was thus 98%. Lymphocyte DNA was available for 486 of the patients who had agreed to participate in the study.

Healthy population controls were drawn from the Finnish National Population Register covering the same catchment area of the cases. In all, 514 controls were interviewed in parallel with the cancer cases, for a final participation rate of 72%. Of these, lymphocyte DNA was available for 492 subjects.

Four controls and three cancer cases were excluded from the study because of the poor quality of their DNA. Additionally, we excluded four population controls with earlier breast cancer diagnosis, as well as two controls of non-Finnish origin. Therefore, our final study population contained 483 incident breast cancer cases, and 482 healthy subjects, all Finnish Caucasians.

The malignant breast tumors were categorized on the basis of UICC Tumor-Node-Metastasis classification (19) . Women having axillary lymph node-positive disease (n = 164) or metastatic breast cancer (stage IV; n = 16) at diagnosis were considered advanced cases. The cases diagnosed with a tumor confined to the breast, either in situ (n = 40) or invasive (n = 253), were designated as local. This categorization could not be performed for 10 patients because of missing information on lymph node involvement.

CYP17 Genotyping.
The CYP17 genotype was determined by a PCR-based method essentially as described by Feigelson et al. (6) . Briefly, subsequent to the PCR with specific primers (5'-CAT TCG CAC TCT GGA GTC-3' and 5'-AGG CTC TTG GGG TAC TTG-3'), 15-µl aliquots of the amplification products were digested for 2 h at 37°C using MspAI (Promega). Presence of the MspA1 restriction site differentiated the A2 allele from the A1 allele, which lacks the site. To ensure the quality of the laboratory analyses, two independent readers interpreted the results, any sample with ambiguous results was reanalyzed, and a random selection of 10% of all samples was repeated. No discrepancies were discovered upon replicate testing.

Statistical Analysis.
The association between CYP17 alleles and breast cancer was examined using unconditional logistic regression. All ORs and 95% CIs were adjusted for age (5-year intervals), age at menarche (12, 13–14, 15 years), age at FFTP (nulliparous, <25, 25–30, >30 years), number of children (continuous), history of benign breast disease (no/yes), first-degree (mother, sister, daughter) family history of breast cancer (no/yes), WHR (0.91, >0.91), use of oral contraceptives (never/ever), and postmenopausal use of estrogen (never/ever). If data on any of the adjusting variables was missing, subjects were excluded from the logistic regression analyses.

The putative low-risk genotype A1/A1 served as a reference category. All analyses were first performed separately for subjects with A1/A2 and A2/A2 genotypes. However, as no clear gene dose effects were observed, the A1/A2 and A2/A2 genotypes were combined to increase the statistical power in stratified analysis.

All results are shown stratified by menopausal status at the time of the diagnosis of the case patient. Women who reported natural menopause or had undergone bilateral oophorectomy were classified as postmenopausal. Hysterectomized women with intact ovaries/ovary (40 cases, 41 controls) and women for whom the details of the operation were unknown (6 cases, 2 controls) were also classified postmenopausal if they were no longer menstruating and were older than 51 years (median for menopause in Finnish women). All of the others were classified premenopausal. WHR, BMI, and age at FFTP were dichotomized on the basis of the median values for population controls. The methods regarding clinical data and medical history have been described in detail elsewhere (18) .

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Because the controls were younger, at 53.5 years (SD, 10.9 years), than the cases at 59.0 years (SD, 14.3 years; P < 0.001), the proportion of premenopausal women was higher among population controls (42%) compared with breast cancer patients (34%). The mean age at menarche [13.6 years (SD, 1.5 years for controls), 13.8 years (SD, 1.6 years) for cases] and age at first term pregnancy [24.6 years (SD, 4.1 years) for controls, 24.9 years (SD, 4.6 years) for cases] was similar in both groups. First-degree family history of breast cancer was associated with an increased risk of this malignancy (OR, 2.53; 95% CI, 1.48–4.31; Table 1 ). Much weaker, but yet significant, associations were observed for the history of benign breast disease (OR, 1.33; 95% CI, 1.01–1.75) and WHRs over 0.91 (OR, 1.38; 95% CI, 1.06–1.81). A significantly decreased risk, on the other hand, was observed for women who reportedly had ever used oral contraceptives (OR, 0.66; 95% CI, 0.48–0.91), and for women with at least one child (OR, 0.53; 95% CI, 0.37–0.77).

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

Similarly to later age at menarche, the benefit of having children was found only among the premenopausal women with the A1/A1 genotype (OR, 0.22; 95% CI, 0.07–0.62). This observation is compatible with the hypothesis that the protection against breast cancer is reduced among women with the A2 allele containing genotypes because of elevated baseline levels of circulating steroid hormones. Contrasting the finding of Haiman et al. (8) , the same was not found for the earlier age at FFTP.

It should be noted that even if our study contained a reasonably large sample size, the number of subjects in the subgroup analysis was relatively low. The findings should thus be interpreted with caution before confirmed in future studies.

As the above-described significant associations were mainly confined to premenopausal women, this supports the view that the etiology of breast cancer may differ by menopausal status. The menopausal status should thus be taken properly into account in the analyses. However, in the study of Weston et al. (16) with 363 cases and 240 patient controls of Caucasian, African-American, and Latino origin, no detailed data were given about the potential effect of menopausal status. In the study by Kristensen et al. (15) including 510 Norwegian cases and 210 controls, the controls were 20–44 years old (i.e., mostly premenopausal), whereas the cases were 27–91 years old (i.e., both pre- and postmenopausal). Inversely, in the largest study done thus far, by Dunning et al. (12) , the breast cancer patients (n = 835) were all diagnosed under the age of 55 years (i.e., mostly premenopausal), whereas the age at diagnosis of the controls (n = 591) varied between 45 and 74 years (i.e., both pre- and postmenopausal). They acknowledged the problem, especially because the positive findings of Feigelson et al. (9) were from considerably older cases (63 years) and controls (61 years), and stressed the possibility that CYP17 genotype effects might be age-specific with marked effects seen only among older cases, raising a need for additional studies involving older study subjects. However, the present study included relatively large group of postmenopausal subjects with mean ages of 61 years and 66 years for the controls and cases, respectively, but no significant genotype effects were seen.

Although there was a clear tendency of lower risk of advanced breast cancer in carriers of at least one A2 allele, the association did not reach statistical significance. Moreover, the A2 allele-containing genotypes were not significantly associated with disease status (local versus advanced) among the cases. We therefore cannot totally rule out the possibility that the apparent effect modification by disease status was a chance finding. This remains to be evaluated in future studies.

Excluding the above study of Dunning et al. (12) , one weakness in the previous studies was their small study size. Despite being one of the largest, our study barely reached the 90% power at the 5% significance level to detect a 1.5-fold moderate effect in the risk associated with the variant allele. Most of the previous studies included considerably smaller study populations than ours and may thus have lacked statistical power for reliable interpretations. Evidently, larger studies are thus needed to obtain more precise risk estimates.

Because the genotype effects have been shown to differ by race, ethnically mixed study populations are also anticipated to be a potential source of bias in the previous studies. More studies in ethnically diverse but homogenous study populations are thus needed. In this respect, one of the strengths of our study may be the inclusion of only cases and controls who were confirmed to be of genetically homogenous Finnish origin.

It has to be noted that the original study of Feigelson et al. (9) , showing a 2.5-fold (95% CI, 1.07–5.94) increased risk for advanced breast cancer, suffered from all of the above-mentioned weaknesses, i.e., included racially mixed cases and controls, had relatively small study size, and lacked information on the menopausal status of the subjects. The two other positive findings, on the other hand, were for specific subgroups, i.e., for young (<37 years) females (10) , and male breast cancer (11) . The evidence for CYP17 genotype contributing in the overall breast cancer risk is thus relatively weak, further suggesting a minor role for this gene in the etiology of breast cancer.

To conclude, our findings suggest that CYP17 polymorphism has no major effect in overall breast cancer proneness, but may modify the risk of breast cancer for certain subgroups.

	Acknowledgments

 
We thank our colleagues at the Kuopio Cancer Research Center and A. K. Lyytinen, R.N., for data collection.

	Footnotes

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ The work was supported by the Academy of Finland, the Finnish Konkordia Foundation, and EVO funds from Kuopio University Hospital.

² To whom requests for reprints should be addressed, at Molecular Epidemiology Group, Department of Industrial Hygiene and Toxicology, Finnish Institute of Occupational Health, Topeliuksenkatu 41 a A, FIN-00250 Helsinki, Finland. Phone: 358-9-4747-2204; Fax: 358-9-4747-2110; E-mail: Ari.Hirvonen{at}occuphealth.fi

³ The abbreviations used are: OR, odds ratio; CI, confidence interval; WHR, waist:hip ratio; BMI, body mass index; FFTP, first full-term pregnancy.

Received 5/ 3/00; revised 9/14/00; accepted 9/22/00.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Feigelson H. S., Henderson B. E. Estrogens and breast cancer. Carcinogenesis (Lond.), 17: 2279-2284, 1996.[Free Full Text]
2. Dunning, A. M., Healey, C. S., Pharoah P. D. P., Teare, M. D., Ponder, B. A. J., and Easton, D. F. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol., Biomark. Prev., 8: 843–854, 1999.
3. Picado-Leonard J., Miller W. L. Cloning and sequencing of the human gene for P450c17 (steroid 17 a-hydroxylase/17, 20 lyase): similarity with the gene for P450c21. DNA, 6: 439-448, 1987.[Medline]
4. Brentano S. T., Picado-Leonard J., Mellon S. H., Moore C. C. D., Miller W. L. Tissue-specific cyclic adenosine 3',5'-monophosphate-induced and phorbol ester-repressed transcription from the human P450c17 promoter in mouse cells. Mol. Endocrinol., 4: 1972-1979, 1990.[Abstract]
5. Carey A. H., Waterworth D., Patel K., White D., Little J., Novelli P., Franks S., Williamson R. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum. Mol. Genet., 3: 1873-1876, 1994.[Abstract/Free Full Text]
6. Feigelson H. S., Shames L. S., Pike M. C., Coetzee G. A., Stanczyk F. Z., Henderson B. E. Cytochrome P450c17a gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res., 58: 585-587, 1998.[Abstract/Free Full Text]
7. Feigelson H. S., McKean-Cowdin R., Pike M. C., Coetzee G. A., Kolonel L. N., Nomura A. M. Y., Marchand L. L., Henderson B. E. Cytochrome P450c17a gene (CYP17) polymorphism predicts use of hormone replacement therapy. Cancer Res., 59: 3908-3910, 1999.[Abstract/Free Full Text]
8. Haiman C. A., Hankinson S. E., Spiegelman D., Colditz G. A., Willett W. C., Speizer F. E., Kelsey K. T., Hunter D. J. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res., 59: 1015-1020, 1999.[Abstract/Free Full Text]
9. Feigelson H. S., Coetzee G. A., Kolonel L. N., Ross R. K., Henderson B. E. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res., 57: 1063-1065, 1997.[Abstract/Free Full Text]
10. Bergman-Jungestrom M., Gentile M., Lundin A-C. , the South-East Breast Cancer Group, and Wingren, S. Association between CYP17 gene polymorphism and risk of breast cancer in young women. Int. J. Cancer, 84: 350-353, 1999.[Medline]
11. Young I. E., Kurian K. M., Annink S., Kunkler I. H., Anderson V. A., Cohen B. B., Hooper M. L., Wyllie A. H., Steel C. M. A polymorphism in the CYP17 gene is associated with male breast cancer. Br. J. Cancer, 81: 141-143, 1999.[Medline]
12. Dunning A. M., Healey C. S., Pharoah P. D. P., Foster N. A., Lipscombe J. M., Redman K. L., Easton D. F., Day N. E., Ponder B. A. J. No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. Br. J. Cancer, 77: 2045-2047, 1998.[Medline]
13. Helzlsouer K. J., Huang H-Y., Strickland P. T., Hoffman S., Alberg A. J., Comstock G. W., Bell D. A. Association between CYP17 polymorphisms and the development of breast cancer. Cancer Epidemiol. Biomark. Prev., 7: 945-949, 1998.[Abstract]
14. Huang C-S., Chern H-D., Chang K-J., Cheng S-W., Hsu S-M., Shen C-Y. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res., 59: 4870-4875, 1999.[Abstract/Free Full Text]
15. Kristensen V. N., Haraldsen E. K., Anderson K. B., Lonning P. E., Erikstein B., Kåresen R., Gabrielsen O. S., Borresen-Dale A-L. CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1. Cancer Res., 59: 2825-2828, 1999.[Abstract/Free Full Text]
16. Weston A., Pan C., Bleiweiss I. J., Ksieski H. B., Roy N., Maloney N., Wolff M. S. CYP17 genotype and breast cancer risk. Cancer Epidemiol. Biomark. Prev., 7: 941-944, 1998.[Abstract]
17. Coughlin S. S., Piper M. Genetic polymorphisms and risk of breast cancer. Cancer Epidemiol. Biomark. Prev., 8: 1023-1320, 1999.[Free Full Text]
18. Männistö S., Pietinen P., Pyy M., Palmgren J., Eskelinen M., Uusitupa M. Body-size indicators and risk of breast cancer according to menopause and estrogen receptor status. Int. J. Cancer, 68: 8-13, 1996.[Medline]
19. Sobin, L. H., Wittekind. C. Breast tumors. In: L. H. Sobin and C. Wittekind (eds.), UICC Classification of Malignant Tumors, Ed. 5, pp. 123–130. New York: Wiley-Liss, Inc., 1997.

This article has been cited by other articles:

				Y. Chen, M. D. Gammon, S. L. Teitelbaum, J. A. Britton, M. B. Terry, S. Shantakumar, S. M. Eng, Q. Wang, I. Gurvich, A. I. Neugut, et al. Estrogen-biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk: results from the Long Island Breast Cancer Study Project Carcinogenesis, April 1, 2008; 29(4): 766 - 771. [Abstract] [Full Text] [PDF]

				M. Henningson, U. Johansson, A. Borg, H. Olsson, and H. Jernstrom CYP17 genotype is associated with short menstrual cycles, early oral contraceptive use and BRCA mutation status in young healthy women Mol. Hum. Reprod., April 1, 2007; 13(4): 231 - 236. [Abstract] [Full Text] [PDF]

				G. Jasienska, M. Kapiszewska, P. T. Ellison, M. Kalemba-Drozdz, I. Nenko, I. Thune, and A. Ziomkiewicz CYP17 Genotypes Differ in Salivary 17-{beta} Estradiol Levels: A Study Based on Hormonal Profiles from Entire Menstrual Cycles. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2131 - 2135. [Abstract] [Full Text] [PDF]

				N. C. Onland-Moret, C. H. van Gils, M. Roest, D. E. Grobbee, and P. H.M. Peeters Cyp17, Urinary Sex Steroid Levels and Breast Cancer Risk in Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 815 - 820. [Abstract] [Full Text] [PDF]

				H. S. Kok, N. C. Onland-Moret, K. M. van Asselt, C. H. van Gils, Y. T. van der Schouw, D. E. Grobbee, and P. H.M. Peeters No association of estrogen receptor {alpha} and cytochrome P450c17{alpha} polymorphisms with age at menopause in a Dutch cohort Hum. Reprod., February 1, 2005; 20(2): 536 - 542. [Abstract] [Full Text] [PDF]

				B. K. Dunn, D. L. Wickerham, and L. G. Ford Prevention of Hormone-Related Cancers: Breast Cancer J. Clin. Oncol., January 10, 2005; 23(2): 357 - 367. [Abstract] [Full Text] [PDF]

				J. M. Hartikainen, H. Tuhkanen, V. Kataja, A. M. Dunning, A. Antoniou, P. Smith, A. Arffman, M. Pirskanen, D. F. Easton, M. Eskelinen, et al. An Autosome-Wide Scan for Linkage Disequilibrium-Based Association in Sporadic Breast Cancer Cases in Eastern Finland: Three Candidate Regions Found Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 75 - 80. [Abstract] [Full Text] [PDF]

				J. M. Pellikainen, K. M. Ropponen, V. V. Kataja, J. K. Kellokoski, M. J. Eskelinen, and V.-M. Kosma Expression of Matrix Metalloproteinase (MMP)-2 and MMP-9 in Breast Cancer with a Special Reference to Activator Protein-2, HER2, and Prognosis Clin. Cancer Res., November 15, 2004; 10(22): 7621 - 7628. [Abstract] [Full Text] [PDF]

				L. Sharp, A. H. Cardy, S. C. Cotton, and J. Little CYP17 Gene Polymorphisms: Prevalence and Associations with Hormone Levels and Related Factors. A HuGE Review Am. J. Epidemiol., October 15, 2004; 160(8): 729 - 740. [Abstract] [Full Text] [PDF]

				M J Pellikainen, T T Pekola, K M Ropponen, V V Kataja, J K Kellokoski, M J Eskelinen, and V-M Kosma p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis J. Clin. Pathol., March 1, 2003; 56(3): 214 - 220. [Abstract] [Full Text] [PDF]

				J. Pellikainen, V. Kataja, K. Ropponen, J. Kellokoski, T. Pietilainen, J. Bohm, M. Eskelinen, and V.-M. Kosma Reduced Nuclear Expression of Transcription Factor AP-2 Associates with Aggressive Breast Cancer Clin. Cancer Res., November 1, 2002; 8(11): 3487 - 3495. [Abstract] [Full Text] [PDF]

				H. S. Feigelson, R. McKean-Cowdin, and B. E. Henderson Concerning the CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis Mutagenesis, September 1, 2002; 17(5): 445 - 446. [Full Text] [PDF]

				Z. Ye and J. M. Parry Concerning the CYP17 MSPA1 polymorphism and breast cancer risk: a meta-analysis Mutagenesis, September 1, 2002; 17(5): 447 - 448. [Full Text] [PDF]

				M M de Jong, I M Nolte, G J te Meerman, W T A van der Graaf, J C Oosterwijk, J H Kleibeuker, M Schaapveld, and E G E de Vries Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility J. Med. Genet., April 1, 2002; 39(4): 225 - 242. [Abstract] [Full Text] [PDF]

				Z. Ye and J. M. Parry The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis Mutagenesis, March 1, 2002; 17(2): 119 - 126. [Abstract] [Full Text] [PDF]

				K. Mitrunen, P. Sillanpaa, V. Kataja, M. Eskelinen, V.-M. Kosma, S. Benhamou, M. Uusitupa, and A. Hirvonen Association between manganese superoxide dismutase (MnSOD) gene polymorphism and breast cancer risk Carcinogenesis, May 1, 2001; 22(5): 827 - 829. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mitrunen, K. Articles by Hirvonen, A. Search for Related Content PubMed PubMed Citation Articles by Mitrunen, K. Articles by Hirvonen, A.